Q-omics provides the consensus-scored TBC1D30 profile across patient tissues and cancer cell-line models. TBC1D30 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TBC1D30 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TBC1D30 RNA expression shows 19,262 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where TBC1D30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D30 survival associations across molecular data types. TBC1D30 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D30 RNA expression–survival associations across cancer types. High TBC1D30 expression shows unfavorable associations in KIRP, UVM, ACC and LIHC, but favorable associations in SCLC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TBC1D30 RNA expression.
This table summarizes TBC1D30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D30 shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD, LIHC, STAD and HNSC. The KIRC box plot shows higher TBC1D30 RNA expression in normal versus tumor tissue (log2 FC = −0.870, t-test p < 0.001).
This table shows molecular features associated with TBC1D30 in patient tissues and cancer cell lines. In patient samples, TBC1D30 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
